Allergen-Specific Immunotherapy with Monomeric Allergoid in a Mouse Model of Atopic Dermatitis.
Atopic dermatitis (AD) is a widespread and difficult to treat allergic skin disease and is a tough challenge for healthcare. In this study, we investigated whether allergen-specific immunotherapy (ASIT) with a monomeric allergoid obtained by succinylation of ovalbumin (sOVA) is effective in a mouse model of atopic dermatitis. An experimental model of AD was reproduced by epicutaneous sensitization with ovalbumin (OVA). ASIT was performed with subcutaneous (SC) administration of increasing doses of OVA or sOVA. The levels of anti-OVA antibodies, as well as cytokines, were detected by ELISA. Skin samples from patch areas were taken for histologic examination. ASIT with either OVA or sOVA resulted in a reduction of both the anti-OVA IgE level and the IgG1/IgG2a ratio. Moreover, ASIT with sOVA increased the IFN-γ level in supernatants after splenocyte stimulation with OVA. Histologic analysis of skin samples from the sites of allergen application showed that ASIT improved the histologic picture by decreasing allergic inflammation in comparison with untreated mice. These data suggest that ASIT with a succinylated allergen represents promising approach for the treatment of AD.
Department of Nanobiomedical Technology, National Research Center Institute of Immunology, Federal Medical-Biological Agency of Russia, Moscow, Russia.
Nadezda
N
Shershakova
Department of Nanobiomedical Technology, National Research Center Institute of Immunology, Federal Medical-Biological Agency of Russia, Moscow, Russia.
Elena
E
Bashkatova
Department of Nanobiomedical Technology, National Research Center Institute of Immunology, Federal Medical-Biological Agency of Russia, Moscow, Russia.
Alexander
A
Babakhin
Department of Nanobiomedical Technology, National Research Center Institute of Immunology, Federal Medical-Biological Agency of Russia, Moscow, Russia.
Sergey
S
Andreev
Department of Nanobiomedical Technology, National Research Center Institute of Immunology, Federal Medical-Biological Agency of Russia, Moscow, Russia.
Alexandra
A
Nikonova
Department of Nanobiomedical Technology, National Research Center Institute of Immunology, Federal Medical-Biological Agency of Russia, Moscow, Russia.
Igor
I
Shilovsky
Department of Nanobiomedical Technology, National Research Center Institute of Immunology, Federal Medical-Biological Agency of Russia, Moscow, Russia.
Oleg
O
Kamyshnikov
Faculty of Natural Sciences, Imperial College London, London, United Kingdom.
Andrey
A
Buzuk
Department of Skin Allergology and Immunopathology, National Research Center-Institute of Immunology Federal Medical-Biological Agency of Russia, Moscow, Russia.
Olga
O
Elisyutina
Department of Skin Allergology and Immunopathology, National Research Center-Institute of Immunology Federal Medical-Biological Agency of Russia, Moscow, Russia.
Elena
E
Fedenko
Department of Nanobiomedical Technology, National Research Center Institute of Immunology, Federal Medical-Biological Agency of Russia, Moscow, Russia.
Musa
M
Khaitov
D000080384:Allergoids; D000818:Animals; D000917:Antibody Formation; D016207:Cytokines / Q000097:blood; D003876:Dermatitis, Atopic / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D003888:Desensitization, Immunologic / Q000379:methods*; D004195:Disease Models, Animal; D005260:Female; D007073:Immunoglobulin E / Q000378:metabolism; D007074:Immunoglobulin G / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000737:chemistry / Q000276:immunology; D010936:Plant Extracts / Q000276:immunology*
D000080384:Allergoids; D016207:Cytokines; D007074:Immunoglobulin G; D010936:Plant Extracts; D007073:Immunoglobulin E; D010047:Ovalbumin